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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
fermented milk containing Lactobacillus casei DN-114 001 plus yoghurt 
symbiosis (Actimel
®
), and reduction of Clostridium difficile toxins in the gut 
of patients receiving antibiotics and reduced risk of acute diarrhoea in 
patients receiving antibiotics pursuant to Article 14 of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Danone Produits Frais France submitted pursuant to Article 14 of Regulation (EC) 
No 1924/2006 via the Competent Authority of France, the Panel on Dietetic Products, Nutrition and Allergies 
was asked to deliver an opinion on the scientific substantiation of a health claim related to a fermented milk drink 
Actimel
®
 containing Lactobacillus casei (Lc) DN-114 001 and reduction of the presence of Clostridium difficile 
toxins in the gut which reduces the incidence of acute diarrhoea. The Panel considers that the food constituent, 
Actimel
®
, which is the subject of the health claim, is sufficiently characterised. The Panel considers that reducing 
the risk of Clostridium difficile diarrhoea by reducing the presence of C. difficile toxins is a beneficial 
physiological effect. In total the applicant indicated seven publications on human studies, three unpublished 
human studies, eight published and one unpublished non-human studies to be pertinent for the claimed effect. In 
weighing the evidence, the Panel took into account that human and animal studies showed partial survival of Lc 
DN-114 001 during its gastrointestinal passage, that one human intervention study with Actimel
®
 which showed a 
statistically significant risk reduction for CDAD had considerable limitations, that there were only limited data on 
the effect of Actimel
®
 on the reduction C. difficile toxins (the risk factor) in humans, that one study which 
showed an inhibitory effect of Lc DN-114 001 on the growth of C. difficile in vitro does not predict the 
occurrence of an effect against C. difficile in humans, that five further human studies do not support the proposed 
mechanisms by which Actimel
® 
could exert the claimed effect, and that the evidence provided from a further two 
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animal and three in vitro studies does not establish that effects of Actimel
®
 or Lc DN-114 001 in these model 
systems related to immune function and infection can predict the occurrence of such effects in humans. The Panel 
concludes that the evidence provided is insufficient to establish a cause and effect relationship between the 
consumption of Actimel
® 
and a reduction of the risk of C. difficile diarrhoea by reducing the presence of C. 
difficile toxins.  © European Food Safety Authority, 2010. 
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bulgaricus, yoghurt, fermented milk, microbiota, intestine, Clostridium difficile toxin, risk reduction, elderly, 
diarrhoea, antibiotic treatment. 
SUMMARY 
Following an application from Danone Produits Frais France submitted pursuant to Article 14 of 
Regulation (EC) No 1924/2006 via the Competent Authority of France, the Panel on Dietetic 
Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a 
health claim related to a fermented milk drink containing Lactobacillus casei DN-114 001 plus 
yoghurt symbiosis (Actimel
®
) and reduction of the presence of Clostridium difficile (C. difficile) 
toxins in the gut which reduces the incidence of acute diarrhoea.  
The scope of the application was proposed to fall under a health claim referring to disease risk 
reduction. 
The food constituent that is the subject of the health claim is a fermented milk product (Actimel
®
) 
containing Lactobacillus casei DN-114001 and yoghurt cultures (Lactobacillus delbrueckii subsp. 
bulgaricus and Streptococcus thermophilus). The identification and characterisation of the strains 
have been performed by applying phenotypic and genotypic methods. The Panel considers that the 
food constituent, Actimel
®
, which is the subject of the health claim, is sufficiently characterised. 
The claimed effect is “decreases the presence of C. difficile toxins (the risk factor), in the intestinal 
tract and reduces the incidence of acute diarrhoea associated with their presence in the gut of 
susceptible ageing people”. The target population is adults over 50 years old receiving antibiotic 
treatment. The Panel considers that reducing the risk of C. difficile diarrhoea by reducing the presence 
of C. difficile toxins is a beneficial physiological effect.  
In total the applicant indicated seven publications on human studies, three unpublished human studies, 
eight published and one unpublished non-human studies to be pertinent for the claimed effect. In 
addition the applicant provided 65 references related to C. difficile, antibiotic associated diarrhoea 
(AAD), the homeostasis of the intestine and possible mechanisms of “probiotics”. These 65 
references did not refer to Actimel
®
 or its bacterial strains. Three human studies referred to C. difficile 
associated diarrhoea (CDAD). 
In an open non-controlled observational study with 213 elderly patients with a mean age of 88 years 
in two geriatric care wards of a hospital, subjects received twice daily Actimel
®
 for the duration of an 
antibiotic treatment course and 7 days after. The study recorded the incidence of CDAD among 
patients in the geriatric wards for the period November 2007 to January 2008 and compared it with 
the historical incidence in the period of November 2006 to January 2007 when this yoghurt drink had 
not been consumed. The Panel notes that this study was not controlled for factors other than the 
consumption of Actimel
® 
that might have influenced the incidence of CDAD. The Panel considers 
that no conclusion can be drawn from this study for the scientific substantiation of the claimed effect. 
A randomised, double-blind, placebo-controlled pilot (RCT) study was designed to test the feasibility 
of a daily intervention with 2 x 100 ml per day of Actimel
®
 and of a non-fermented acidified dairy 
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drink to investigate the effect on the occurrence of AAD and of CDAD in elderly hospitalised patients 
receiving antibiotics (10 per group). The applicant indicated in the study report that “no statistical 
comparison was performed in the context of a small pilot study”. The Panel agrees that this pilot study 
was underpowered to assess the effects of Actimel
®
 on the incidence of AAD and CDAD. The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claimed effect.   
A RCT with 135 patients of 50 or more years of age under antibiotic treatment studied the effect of 
daily 2 x 100 ml of the yoghurt drink Actimel
®
 compared to 2 x 100 ml daily of a control product on 
the occurrence of AAD as the primary endpoint and CDAD as a secondary endpoint. Test and control 
product were to be consumed twice a day during the course of antibiotic treatment and for one week 
thereafter. As the products were packaged in bottles of different size (100 g Actimel
® 
bottle versus 
200 ml Yazoo
® 
bottle), the hospital pharmacies removed the commercial labels and nursing staff were 
instructed to pour 100 ml of the respective products into a cup and to deliver to the patients in order to 
ensure blinding. According to the study protocol, patients who were discharged from the hospital 
before the end of the intervention were given adequate supplies of test and control products with 
instructions for use labelled on the bottles. The Panel considers that while the blinding procedure used 
in the hospital was adequate, the procedure used following discharge could have resulted in un-
blinding of patients due to the different size of the bottles for the two products. 
“Diarrhoea” was defined as more than two liquid stools a day for three or more days in quantities in 
excess of normal for each patient. According to the study protocol, stool samples of all patients 
should have been tested at baseline, when diarrhoea was reported and at the end of the trial. The 
follow-up of 12 subjects of the Actimel
®
 group and of 10 subjects of the control group could not be 
completed. In a complete- case analysis (per-protocol analysis), the authors reported AAD for 7 out of 
57 patients in the Actimel
®
 group and for 19 out of 56 patients of the control group. In none of the 
patients in the Actimel
®
 group and in 9 out of 53 of the control group diarrhoea was associated with a 
stool sample positive for C. difficile toxins. This corresponds to a statistically significant 22 % (95 % 
CI: 7-37) and 17 % (95 % CI: 7-27) absolute risk reduction for the occurrence of AAD and CDAD, 
respectively. The Panel notes that C. difficile toxins were only measured in patients who developed 
AAD and that there were no data on the effect of Actimel
®
 on the occurrence of C. difficile toxins in 
the faeces of patients without AAD. On request by EFSA, the applicant provided a re-assessment of 
the data with and without data imputation for the non-completers. The applicant provided a re-
assessment with data imputation assuming that a) none of the 22 drop outs had AAD and b) that 20 % 
in both groups had AAD. The results remained statistically significant (p < 0.05) in favour of the test 
product for both scenarios. The Panel notes that statistical significance is sensitive to the treatment of 
the missing data and that no data imputation has been applied for more conservative scenarios than 
20 % assumed occurrence of AAD. 
The Panel notes a number of weaknesses in this study: potential bias through un-blinding of the 
patients to the products; the lack of data on the presence of C. difficile toxins (the risk factor) in the 
faeces of patients at the end of the intervention; no scenario has been applied for the missing data 
imputation for more conservative scenarios than 20 % assumed occurrence of AAD. The Panel 
considers that the weaknesses of this study limit its value as a source of data to substantiate the claim. 
An in vitro study was provided on the capability of Lc DN-114 001 to inhibit the growth of C. 
difficile. According to the summary report the supernatant of Lc DN-114 001 was tested with the 
“overlay method” modified by Danone, for its capacity to inhibit the in vitro growth of Salmonella 
thyphimurium, Listeria monocytogenes and C. difficile. According to the data provided, the 
supernatant of Lc DN-114 001 tested positive for its capability to inhibit the growth of all three 
pathogens. The Panel considers that the results of this in vitro study do not predict the occurrence of 
such an inhibitory effect in humans.  
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Five human studies investigated the kinetics, metabolism and survival of Lc DN-114 001 and its 
impact on the human microbiota during its gastrointestinal transit. These studies demonstrated that Lc 
DN-114 001 can partially survive the gastrointestinal transit. A study demonstrated the expression of 
10 genes of Lc DN-114 001 in human faeces after gastrointestinal transit and did not find evidence for 
multiplication. Results from animal studies showed that Lc DN-114 001 can partially survive 
gastrointestinal transit in human flora-associated mice and rats and is excreted without detectable 
multiplication with the same kinetics as the inert transit marker Bacillus subtilis spores. The Panel 
notes that human and animal data consistently showed partial survival of Lc DN-114 001 during its 
gastrointestinal passage without detectable multiplication.  
Regarding possible mechanisms by which Actimel
®
 could reduce the risk of C. difficile diarrhoea by 
reducing the presence of C. difficile toxins, the applicant suggested that Actimel
®
 increased 
colonisation resistance against pathogens and inhibited pathogen proliferation by modulation of the 
intestinal microbiota, reduction of the gut epithelial permeability, modulation of gut epithelial 
receptors and induction of specific IgA production.  
The applicant provided two human studies on the effect of Actimel
®
 on gastrointestinal infections and 
gastrointestinal pathogens, but which did not refer to C. difficile. In a RCT with 1072 elderly 
volunteers consuming 2 x 100 ml Actimel
®
 per day over 3 months there was no difference in the 
incidence of common infectious diseases, the incidence and duration of gastrointestinal infections, the 
occurrence of fever, the occurrence of pathogens, the number of prescribed medication and 
immunological parameters. In another RCT, 250 young adult volunteers enrolled in firefighting 
training consumed 2 x 100 ml Actimel
®
 per day over 7 weeks. There was no difference in the 
incidence of common infectious diseases, the incidence of gastrointestinal infections, the occurrence 
of fever, the occurrence of pathogens in faeces and the number of prescribed medication. The Panel 
notes that no information has been provided on C. difficile. The Panel considers that these two RCTs 
do not support an effect of Actimel
®
 on the reduction of gastrointestinal infections or gastrointestinal 
pathogens in humans. 
Three other human studies addressed effects on the intestinal microbiota. In an uncontrolled human 
trial with 12 healthy subjects no statistically significant change occurred after 10 days of daily 
consumption of 300 ml Actimel
® 
 in either the dominant members of the faecal microbiota, bacterial 
enzyme activities, pH and metabolites such as short-chain fatty acids.  This was confirmed by another 
human trial in 7 volunteers after 8 days of daily consumption of  300 ml Actimel
®
  which did not find 
any statistically significant change of the proportions of 7 phylogenetic groups . Also a study on the 
effect of a daily intake of 125 g Actimel
®
 in 39 infants and young children of 10 -18 months of age, 
did not find any statistically significant modification of the number of total anaerobes, bifidobacteria, 
bacteroides, and enterobacteria, bacterial metabolites and bacterial enzyme activities in faeces at the 
end of a 30-day intervention. Based on the parameters measured, the Panel considers that the three 
human studies do not provide evidence that Actimel
®
 can modulate the human gut microbiota.  
The applicant provided another two animal studies and three in vitro studies on possible effects of 
Actimel
®
 or Lc DN-114 001 in model systems related to immune function and infection. The Panel 
notes that none of these five studies investigated C. difficile. The Panel considers that the evidence 
provided does not establish that effects of Actimel
®
 or Lc DN-114 001 observed in these animal and 
in vitro studies can predict the occurrence of effects on immune function or infection in humans. 
In weighing the evidence, the Panel took into account that human and animal studies showed partial 
survival of Lc DN-114 001 during its gastrointestinal passage, that one human intervention study with 
Actimel
®
 which showed a statistically significant risk reduction for CDAD had considerable 
limitations, that there were only limited data on the effect of Actimel
®
 on the reduction C. difficile 
toxins (the risk factor) in humans, that one study which showed an inhibitory effect of Lc DN-114 001 
on the growth of C. difficile in vitro does not predict the occurrence of an effect against C. difficile in 
humans, that five further human studies do not support the proposed mechanisms by which Actimel
® 
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could exert the claimed effect, and that the evidence provided from a further two animal and three in 
vitro studies does not establish that effects of Actimel
®
 or Lc DN-114 001 in these model systems 
related to immune function and infection can predict the occurrence of such effects in humans.  
The Panel concludes that the evidence provided is insufficient to establish a cause and effect 
relationship between the consumption of Actimel
® 
and reduction of the risk of C. difficile diarrhoea 
by reducing the presence of C. difficile toxins. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
that Regulation and are authorised in accordance with this Regulation and included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of that 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children‟s development and health in a Community list of 
permitted claims. 
According to Article 15 of that Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, who will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
Steps taken by EFSA: 
 The application was received on 07/09/2009. 
 The scope of the application was proposed to fall under a health claim referring to disease 
risk reduction. 
 The scientific evaluation procedure started on 15/09/2009. 
 On 10-12/11/2009, 24–26/03/2010 and on 06/07/2010, EFSA requested the applicant to 
supplement additional particulars to accompany the application.  
 The applicant submitted the responses to EFSA on 11/01/2010, 14/06/2010, 27/08/2010 and 
on 04/10/2010. 
 During the meeting on 10-12/11/2010, the NDA Panel, after having evaluated the overall data 
submitted, adopted an opinion on the scientific substantiation of a health claim related to 
Lactobacillus casei DN 114001 plus yoghurt cultures (Actimel
®
) and  reducing the risk of 
Clostridium difficile associated diarrhoea by reducing the presence of C. difficile toxin. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: Lactobacillus casei DN 114001 
plus yoghurt cultures (Actimel
®
), and reduction of C. difficile toxins in the gut of patients receiving 
antibiotics and reduced risk of acute diarrhoea in patients receiving AB. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of Lactobacillus casei DN 114001 plus yoghurt symbiosis (Actimel
®
), a positive assessment of its 
safety, nor a decision on whether Actimel
®
 is, or is not, classified as a foodstuff. It should be noted 
that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006. 
                                                     
 
4 European Parliament and Council (2006). Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 
20 December 2006 on nutrition and health claims made on foods. Official Journal of the European Union OJ L 404, 
30.12.2006. Corrigendum OJ L 12, 18.1.2007, p. 3–18. 
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It should also be highlighted that the scope, the proposed wording of the claim and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
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Information provided by the applicant 
Applicant’s name and address: Danone France; 150 Boulevard Victor Hugo, 93589 Saint Ouen, 
Cedex, France. 
The applicant indicates proprietary rights and confidentiality of unpublished study reports (Bulpitt, 
2009; Bulpitt CJ and Hickson M, 2010; Houlder et al., 2009), an unpublished study protocol (D'Souza 
et al., 2003), an unpublished manuscript (Guimaraes et al., 2010), an abstract and the study synopsis 
of a study by Niborski et al. (2009) and an unpublished in vitro study (Danone Research, 2010). In 
addition the applicant claims proprietary rights of data related to the strain Lactobacillus casei DN-
114 001, to the composition, manufacturing and quality control of Actimel
®
, stability information, and 
bioavailability data, presented in the dossier. The claim for proprietary rights include the published 
studies by Djouzi et al. (1997), Guerin-Danan et al. (1998), Guillemard et al. (2010), Oozeer et al. 
(2002, 2004, 2006), Parassol et al. (2005) and Rochet et al. (2006; 2008).  
Food/constituent as stated by the applicant 
The food is a fermented milk product containing Lactobacillus casei DN-114001 and yoghurt cultures 
(Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus). This product is 
commercially available under the brand name Actimel
®
, the tested food. 
Health relationship as claimed by the applicant 
According to the applicant, the presence of C. difficile toxins in the gut is one of the risk factors of 
developing Clostridium associated acute diarrhoea. This risk factor occurs in combination with other 
factors such as ageing, antibiotic therapy, genetic background or impaired immune response. 
According to the applicant the tested food decreases the presence of C. difficile toxins (the risk 
factor), in the intestinal tract and reduces the incidence of acute diarrhoea associated with their 
presence in the gut of susceptible ageing people. 
Wording of the health claim as proposed by the applicant 
Fermented milk containing the probiotic Lactobacillus casei DN-114001 and yogurt symbiosis 
decreases presence of Clostridium difficile toxins in the gut (of susceptible ageing people). Presence 
of Clostridium difficile toxins is associated with the incidence of acute diarrhoea. 
Specific conditions of use as proposed by the applicant 
The target population covered by this application encompasses a subgroup of the general adult 
population, i.e. ageing adults over 50 years old that are receiving antibiotic therapy. 
The effective daily consumption of the tested food is 200 g of the fermented milk containing at least 
10
8
 cfu/g of Lactobacillus casei DN-114001 and yoghurt symbiosis (at least 10
7
 cfu/g), within the 
frame of a balanced diet. 
The product may not be suitable for individuals with a known cow‟s milk allergy. 
Directions for preparation and/or use: The product should be consumed within the indicated shelf life 
and kept refrigerated during storage. 
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Assessment 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is Actimel
®
, a brand for a range of 
sweetened and flavoured fermented milks, as well as fat- and sugar-reduced flavoured versions. 
Actimel
®
 is a fermented milk product with lactic acid bacteria (LAB) incorporated into a dairy matrix 
composed of cow‟s milk exclusively. The LABs in Actimel
®
 are Lactobacillus casei (Lc) DN-114 
001, L. delbrueckii subsp. bulgaricus and S. thermophilus. Two main fermentation pathways are used 
to classify LAB genera as either homofermentative or heterofermentative. L. delbrueckii subsp. 
bulgaricus and S. thermophilus are homofermentative - lactic acid is the primary end-product of 
fermentation, while Lc DN-114 001 is facultatively heterofermentative (end-products of fermentation, 
in addition to lactic acid, include acetic acid and carbon dioxide). According to the dossier provided, 
Actimel
®
 contains at least 10
10
 cfu per 100 g (10
8
 cfu/g) of Lc DN-114 001and 10
9 
cfu (10
7
cfu/g) of L. 
delbrueckii subsp. bulgaricus / S. thermophilus until the end of the shelf-life.  
The strain Lc DN-114 001 has been characterised and was deposited at the Collection Nationale de 
Cultures de Microorganismes at the Institut Pasteur, Paris, France in 1994. Lc DN-114 001 is 
provided to a contract manufacturer and the master strain and working copies are kept in the 
applicant‟s strain collection. The full genome sequence of Lc DN-114 001 was obtained in 2005 and 
analysed in 2006. The full genome sequence is stored in ERGO™ (Bioinformatics suite comparative 
genomics analysis by Integrated Genomics, Inc) data base and is available upon request. The 16S-
rDNA has been sequenced and the genotyping methods Random Amplification of Polymorphic DNA 
(RAPD), Amplified Fragment-Length Polymorphism (AFLP), Multi Locus Sequence Typing (MLST) 
and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) analyses (Diancourt et al., 
2007) have been applied and confirm that the Lc DN-114 001 is a member of the Lactobacillus 
paracasei subsp. paracasei species which is in line with the  classification of the Judicial Commission 
of the International Committee on Systematics of Bacteria (JCICSB, 2008). 
The yogurt starter cultures present in the food have been identified either as L. delbrueckii subsp. 
bulgaricus DN-100 290 or S. thermophilus salivarius subsp. thermophilus DN-001 236 / DN-001 336 
/ DN- 001 460 by sequencing 16S rDNA and genotyping by AFLP, SDS page methods (internal 
reports are available upon request). The strains were deposited in the French National Collection of 
Cultures of Micro-organisms. The applicant provides sufficient information on the species and strain 
identification. 
Since there is a wide range of flavoured fermented milks in the Actimel
®
 brand, the composition of 
these products may be modulated with the addition of other ingredients, at a maximum incorporation 
level of 5 %, such as: fruit, fruit juice or plant concentrate, sugar (sucrose), fibres (oligofructose), 
thickener (tapioca starch), stabilizer (pectin), flavourings and acidity regulators (sodium citrate, citric 
acid).  
The Panel considers that Actimel
®
, the food that is the subject of the health claim, is sufficiently 
characterised.  
2. Relevance of the claimed effect to human health 
The claimed effect is “decreases the presence of C. difficile toxins (the risk factor), in the intestinal 
tract and reduces the incidence of acute diarrhoea associated with their presence in the gut of 
susceptible ageing people”. The target population is adults over 50 years old receiving antibiotic 
treatment. 
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The Panel considers that treatment with certain antibiotics (AB) may be associated with C. difficile 
associated diarrhoea. The presence of C. difficile toxins in the gut may be associated with the 
incidence of acute diarrhoea.  
The Panel considers that reducing the risk of C. difficile diarrhoea by reducing the presence of C. 
difficile toxins is a beneficial physiological effect.  
3. Scientific substantiation of the claimed effect 
The applicant‟s literature search included studies between 1950 and July 2009 published in Medline, 
and between 1974 and July 2009 in EMbase using the online database aggregator Datastarweb. 
Details on the search strategy were given and included keywords such as Danone, Actimel
®
, DN-
114001, Lactobacillus casei, probiotic, Clostridium difficile, human, patient, participant, clinical trial, 
human trial, clinical study, randomisation, double blind, control, cohort study, case control study, 
crossover study, multicenter trial, toxin, diarrhoea, acute diarrhoea, antibiotic associated diarrhoea 
(AAD).  
In total the applicant indicated seven publications on human studies, three unpublished human studies, 
eight published and one unpublished non-human studies to be pertinent for the claimed effect. In 
addition the applicant provided 65 references related to C. difficile, AAD, the homeostasis of the 
intestine and possible mechanisms of “probiotics” which provided a general scientific background of 
this field. These 65 references did not refer to Actimel
®
 or its bacterial strains. Three human studies 
referred to C. difficile associated diarrhoea (CDAD). 
In an open non-controlled observational study with 213 elderly patients with a mean age of 88 (80 – 
101) years in two geriatric care wards of a hospital, subjects received twice daily Actimel
®
 for the 
duration of an antibiotic treatment course and 7 days thereafter (Houlder et al., 2009, unpublished). 
The study recorded the incidence of CDAD among patients in the geriatric wards for the period 
November 2007 to January 2008 and compared it with the historical incidence in the period of 
November 2006 to January 2007 when Actimel
®
 had not been consumed. The Panel notes that this 
study was not controlled for factors other than the consumption of Actimel
® 
that might have 
influenced the incidence of CDAD, e.g. differences in the use of antibiotics between the two periods. 
The Panel considers that no conclusion can be drawn from this study for the scientific substantiation 
of the claimed effect. 
A RCT pilot study was designed to test the feasibility of a daily intervention with 2 x 100 ml per day 
of Actimel
®
 and of a non-fermented acidified dairy drink to investigate the effect on the occurrence of 
AAD and of CDAD in elderly hospitalised patients receiving antibiotics (10 subjects per group). 
(Bulpitt, 2009, unpublished). The applicant commented in the study report that “no statistical 
comparison was performed in the context of a small (20 subjects) pilot study”. The Panel agrees that 
this pilot study was underpowered to assess the effects of Actimel
®
 on the incidence of AAD and 
CDAD. The Panel considers that no conclusions can be drawn from this study for the scientific 
substantiation of the claimed effect.   
A RCT aimed to recruit 164 hospitalised patients of 50 or more years of age under antibiotic 
treatment to study the effect of daily 2 x 100 ml of the yoghurt drink Actimel
®
 compared to 2 x 
100 ml daily of a control product on the occurrence of AAD as the primary endpoint and CDAD as a 
secondary endpoint (Hickson et al., 2007; Bulpitt and Hickson, 2010 - unpublished). Other secondary 
study endpoints were lactobacillus counts in the stool, IgA levels specific to C. difficile in the stools, 
urinary indican (“as a marker for bacterial colonization in the gut”), use of AB (metronidazole and 
vancomycin to treat C. difficile infections), length of hospital stays, costs issues, C-reactive protein 
and white blood cell counts (WCC). The recruitment was stopped when 135 subjects were enrolled 
before reaching the target sample size of 164 subjects (82 per group) derived from the power 
calculation and predefined in the study protocol. The recruited patients had a mean age of 73.8 years. 
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Baseline characteristics were reported and were similar in both groups. One patient in each group was 
positive for C. difficile toxin at baseline but had no diarrhoea (neither patient subsequently developed 
diarrhoea). 
The control product was Yazoo
®
, an ultra-high temperature treated, non-fermented, sweetened, 
flavoured dairy drink which was similar in colour and consistency to Actimel
®
. Test and control 
product were to be consumed twice a day during the course of AB and for one week after the course 
finished. As the products were packaged in bottles of different size (100 g Actimel
® 
bottle versus 
200 ml Yazoo
® 
bottle), the hospital pharmacies removed the commercial labels and nursing staff were 
instructed to pour 100 ml of the respective products into a cup and to deliver to the patients in order to 
ensure blinding. According to the study protocol, patients who were discharged from the hospital 
before the end of the intervention were given adequate supplies of test and control products with 
instructions for use labelled on the bottles (D‟Souza et al., 2003). The Panel considers that while the 
blinding procedure used in the hospital was adequate, the procedure used following discharge could 
have resulted in un-blinding of patients due to the different size of the bottles for the two products. 
Approximately 2/3 (at least 84 subjects) of the patients finished the intervention with the Actimel
®
 
and control product not in the hospital but at home. 
“Diarrhoea” was defined as more than two liquid stools a day for three or more days in quantities in 
excess of normal for each patient. According to the applicant, diarrhoea during hospitalisation was 
reported by nurses and confirmed by one or more researchers and stool samples were taken. Post-
discharge monitoring of diarrhoea was conducted via telephone by researcher (at least once per week) 
or with a questionnaire which was completed by the patient to record the presence or absence of 
diarrhoea. In the case of reported diarrhoea, the subjects were called to the hospital for a C. difficile 
toxin test of the stool. An ELISA kit, suitable to detect C. difficile toxin A and B was used. According 
to the study protocol, stool samples of all patients should have been tested at baseline, when diarrhoea 
was reported and at the end of the trial.  
One hundred-thirteen patients completed the trial (drop-out rate: 16.3 %). The follow-up of 12 
subjects of the Actimel
®
 group and of 10 subjects of the control group could not be completed. In a 
complete- case analysis (per-protocol analysis), the authors reported AAD for 7 out of 57 patients in 
the Actimel
®
 group and for 19 out of 56 patients of the control group. In none of the patients in the 
Actimel
®
 group and in 9 out of 53 of the control group diarrhoea was associated with a stool sample 
positive for C. difficile toxins. This corresponds to a statistically significant 22 % (95 % CI: 7-37) and 
17 % (95 % CI: 7-27) absolute risk reduction for the occurrence of AAD and CDAD, respectively. 
Data on C. difficile toxin testing from 4 subjects with reported diarrhoea were missing (1 in Actimel
®
 
group versus 3 in the control group). The applicant provided an analysis on the occurrence of AAD 
before and after hospital discharge. There was no significant difference between groups in the 
occurrence of AAD before hospital discharge (6 in the Actimel
®
 group versus 7 in the placebo group), 
but a significant difference between groups was observed after the subjects were discharged from the 
hospital (0 in the Actimel
®
 group versus 12 in the control group). According to the study report other 
secondary study endpoints (lactobacillus counts in the stool, C. difficile specific IgA levels in the 
stools, urinary indican, use of metronidazole and vancomycin to treat C. difficile infections, length of 
hospital stays, C-reactive protein and WCC) were not analysed due to insufficient data or techniques. 
The Panel notes that C. difficile toxins were only measured in patients who developed AAD and that 
there were no data on the effect of Actimel
®
 on the occurrence of C. difficile toxins in the faeces of 
patients without AAD.  
On a request of EFSA, the applicant provided a re-assessment of the data with and without data 
imputation for the non-completers, taking into account the covariates “number” and “type of 
prescribed AB” and the “duration of the AB treatment”. For the data imputation, two scenarios were 
conducted assuming that a) none of the 22 drop outs had AAD and b) that 20 % in both groups had 
AAD. According to the applicant, 20 % represents the mean for the range of 5 – 35 % occurrence of 
AAD reported in the literature (referring to all ages, hospitalized and non-hospitalized patients). The 
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results remained statistically significant (p < 0.05) in favour of the test product for both scenarios. 
The Panel notes that statistical significance is sensitive to the treatment of the missing data and that 
no data imputation has been applied for more conservative scenarios than 20 % assumed occurrence 
of AAD.  
The Panel notes a number of weaknesses in this study: potential bias through un-blinding of the 
patients to the products; the lack of data on the presence of C. difficile toxins (the risk factor) in the 
faeces of patients at the end of the intervention; no scenario has been applied for the missing data 
imputation for more conservative scenarios than 20 % assumed occurrence of AAD. The Panel 
considers that the weaknesses of this study limit its value as a source of data to substantiate the claim. 
The applicant provided an in vitro study on the capability of Lc DN-114 001 to inhibit the growth of 
C. difficile (Danone Resarch, 2010, unpublished). According to the summary report the supernatant of 
Lc DN-114 001 was tested with the “overlay method” modified by Danone, for its capacity to inhibit 
the in vitro growth of Salmonella thyphimurium, Listeria monocytogenes and C. difficile. The strain 
Lc DN-114 001 was grown overnight and lactic acid neutralised culture supernatant was applied for 
24 h to agar plates with pathogen colonies, in anaerobic conditions. Plates were then checked visually 
for the presence of growth inhibition areas around pathogens colonies. According to the data 
provided, the supernatant of Lc DN-114 001 tested positive for its capability to inhibit the growth of 
all three pathogens. The Panel considers that the results of this in vitro study do not predict the 
occurrence of such an inhibitory effect in humans.  
Five human studies investigated the kinetics, metabolism and survival of Lc DN-114 001 and its 
impact on the human microbiota during its gastrointestinal transit (Guerin-Danan et al., 1998; 
Guimaraes et al., 2010, unpublished; Oozeer et al., 2006; Rochet et al., 2006, 2008). These studies 
demonstrated that Lc DN-114 001 can partially survive the gastrointestinal transit (Oozeer et al. 
2006). Guimaraes et al. (2010, unpublished) demonstrated expression of 10 genes of Lc DN-114 001 
in the faeces after a human gastrointestinal transit and did not find evidence for multiplication. 
Results from animal studies showed that Lc DN-114 001 can partially survive gastrointestinal transit 
in human flora-associated mice and rats and is excreted without detectable multiplication with the 
same kinetics as inert transit marker Bacillus subtilis spores (Djouzi et al., 1997; Oozeer et al., 2002; 
Oozeer et al., 2004). The Panel notes that human and animal data consistently showed partial survival 
of Lc DN-114 001 during its gastrointestinal passage without detectable multiplication.  
Regarding possible mechanisms by which Actimel
®
 could reduce the risk of C. difficile diarrhoea by 
reducing the presence of C. difficile toxins, the applicant suggested that Actimel
®
 increased 
colonisation resistance against pathogens and inhibited pathogen proliferation by modulation of the 
intestinal microbiota, reduction of the gut epithelial permeability, modulation of gut epithelial 
receptors and induction of specific IgA production.  
The applicant provided two human studies on the effect of Actimel
®
 on gastrointestinal infections and 
gastrointestinal pathogens, but which did not refer to C. difficile. In a RCT with 1072 elderly 
volunteers consuming 2 x 100 ml Actimel
®
 per day over 3 months, there was no difference in the 
incidence of common infectious diseases (primary endpoint), the incidence and duration of 
gastrointestinal infections, the occurrence of fever, the occurrence of pathogens, the number of 
prescribed medication and immunological parameters (among other secondary endpoints) (Guillemard 
et al., 2010). In another RCT, 250 young adult volunteers enrolled in firefighting training consumed 2 
x 100 ml Actimel
®
 per day over 7 weeks. There was no difference in the incidence of common 
infectious diseases (primary endpoint), the incidence of gastrointestinal infections, the occurrence of 
fever, the occurrence of pathogens in faeces and medication (among other secondary endpoints) 
(Danone, 2009; Niborski et al., 2009). The authors reported a significant increase of L. paracasei in 
faeces by a detection method which covered also the DN-114 001 strain. The Panel notes that no 
information has been provided on C. difficile. The Panel considers that these two RCTs do not support 
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an effect of Actimel
®
 on reduction of gastrointestinal infections or gastrointestinal pathogens in 
humans. 
Three other human studies addressed effects on the intestinal microbiota. In an uncontrolled human 
trial with 12 healthy subjects after 10 days of daily consumption of 300 ml Actimel
® 
(Rochet et al., 
2006) no statistically significant change occurred in either the dominant members of the faecal 
microbiota (Atopobium, Bacteroides-Prevotella, Bifidobacterium, Clostridium coccoides, 
Faecalibacterium prausnitzii, enterobacteria and Lactobacillus–Enterococcus groups), bacterial 
enzyme activities (α-Galactosidase, β–Galactosidase, β–Glucosidase, β–Glucuronidase, 
Neuraminidase, α-N-Acetylgalactosaminidase, β-N-Acetylgalactosaminidase, α-Fucosidase, 
Reductase, Azoreductase, β-N-Acetylglucosaminidase), pH and metabolites (such as short-chain fatty 
acids).  This was confirmed by another human trial in 7 volunteers after 8 days of daily consumption 
of  300 ml Actimel
®
  (Rochet et al., 2008) which did not find any statistically significant change of the 
proportions of 7 phylogenetic groups (Bacterioides, Bifidobacterium genius, C. coccoides, 
Atopobium, Lactobacilli-Enterococci, Streptococci-Lactococci, and Enterobacteria).  Also Guerin-
Danan et al. (1998) who studied the effect of a daily intake of 125 g Actimel
®
 in 39 infants and young 
children of 10 -18 months of age, did not find any statistically significant modification of the number 
of total anaerobes, bifidobacteria, bacteroides, and enterobacteria, bacterial metabolites and the 
bacterial enzyme activities (β-Galactosidase, α-Glucosidase, Nitrate reductase, Nitroreductase, β-
Glucuronidase, β-Glucosidase) in the faeces at the end of a 30-day intervention. Based on the 
parameters measured, the Panel considers that the three human studies do not provide evidence that 
Actimel
®
 can modulate the human gut microbiota.  
The applicant provided another two animal studies and three in vitro studies on possible effects of 
Actimel
®
 or Lc DN-114 001 in model systems related to immune function and infection. Medici et al. 
(2005) investigated effects of Actimel
®
 on the phagocytic activity of peritoneal macrophages, on IgA
+
 
cells in the intestine and on the colonisation of entero-invasive E. coli in a liver BALB/c mouse 
model.  Guerin-Danan et al. (2001) studied effects of Lc DN-114 001 in SA11 rotavirus infected 
germfree suckling rats. The three in vitro experiments investigated the effect of spent culture 
supernatants of Lc DN-114 001 on the cell surface glycosylation and rotavirus infection of cultured 
intestinal epithelial cells (Freitas et al., 2003), the effect of Lc DN-114 001 on adhesion to and 
invasion of human intestinal epithelial cell lines by adherent-invasive E. coli isolated from Crohn‟s 
disease patients (Ingrassia et al., 2005) and the effects of Lc DN-114 001 on paracellular permeability  
of human colon epithelial T-84 cell cultures measured by electrical resistance and on the adhesion of 
enteropathogenic E. coli (EPEC) (Parassol et al., 2005). The Panel notes that none of these five 
studies investigated C. difficile. The Panel considers that the evidence provided does not establish that 
effects of Actimel
®
 or Lc DN-114 001 observed in these animal and in vitro studies can predict the 
occurrence of effects on immune function or infection in humans. 
In addition, the applicant provided 35 references on the homeostasis of the intestine and possible 
mechanisms of “probiotics” and 31 references on studies and reviews concerning the epidemiology, 
pathogenesis, risk factors, clinical symptoms, and therapy and management of nosocomial and 
community-acquired C. difficile infections, and diarrhoea associated with antibiotic therapy. A few 
articles concerned the impact of advanced age on the immune system and the human intestinal 
microbiota. These articles provide evidence that hospitalisation, antibiotic treatment and age above 65 
years have been identified as the predominant risk factors for CDAD. Some references reported on 
other risk factors such as age over 60 years, exposure to subjects with CDAD, medication with proton 
pump inhibitors, anti-inflammatory, immunosuppressive and anti-neoplastic drugs (Barbut and Petit, 
2001; Karlström et al., 1998; Kuijper et al., 2008; McFarland, 2008; Wiström et al., 2001). The Panel 
notes the risk factors including the age range of individuals with CDAD described in the literature. 
In weighing the evidence, the Panel took into account that human and animal studies showed partial 
survival of Lc DN-114 001 during its gastrointestinal passage, that one human intervention study with 
Actimel
®
 which showed a statistically significant risk reduction for CDAD had considerable 
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limitations, that there were only limited data on the effect of Actimel
®
 on the reduction C. difficile 
toxins (risk factor) in humans, that one study which showed an inhibitory effect of Lc DN-114 001 on 
the growth of C. difficile in vitro does not predict the occurrence of an effect against C. difficile in 
humans, that five further human studies do not support the proposed mechanisms by which Actimel
® 
could exert the claimed effect, and that the evidence provided from a further two animal and three in 
vitro studies does not establish that effects of Actimel
®
 or Lc DN-114 001 in these model systems 
related to immune function and infection can predict the occurrence of such effects in humans.  
The Panel concludes that the evidence provided is insufficient to establish a cause and effect 
relationship between the consumption of Actimel
® 
and reduction of the risk of C. difficile diarrhoea 
by reducing the presence of C. difficile toxins. 
CONCLUSIONS 
 The food constituent, Actimel®, that is the subject of the claim is sufficiently characterised.  
 The claimed effect is to decrease the presence of Clostridium difficile toxins in the gut of 
susceptible elderly people. The target population encompasses a subgroup of general adult 
population, i.e. ageing adults over 50 years old that are receiving antibiotics.  
 The Panel considers that the reduction of C. difficile toxin in the gut of patients receiving 
antibiotics maybe beneficial. C. difficile toxin in the gut of patients receiving antibiotics is a 
risk factor in the development of AAD. 
 The evidence provided is insufficient to establish a cause and effect relationship between the 
consumption of Actimel
®
 and reduction of the risk of C. difficile diarrhoea by reducing the 
presence of C. difficile toxins.  
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